B7-H6產(chǎn)品信息
別稱:B7-H6,NCR3LG1,B7 Homolog 6
物種:Human / Cynomolgus
屬性:Protein / Antibody Licensing
標(biāo)記:Biotin-labeled / Unconjugated
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
1. -20°C to -70°C for 12 months in lyophilized state;
2. -70°C for 3 months under sterile conditions after reconstitution.
B7-H6分子背景
B7基因家族在調(diào)節(jié)適應(yīng)性免疫系統(tǒng)中至關(guān)重要。其中之一是最近發(fā)現(xiàn)的B7-H6。人類和大鼠只有一個(gè)B7-H6基因;然而,在爪蟾基因組中的單個(gè)大簇中檢測(cè)到許多B7-H6基因。嵌合抗原受體(CAR)T細(xì)胞療法在臨床試驗(yàn)中已被證明對(duì)B細(xì)胞白血病具有持久和潛在的療效。在這項(xiàng)研究中,靶向NK細(xì)胞激活受體NKp30的配體B7-H6,以創(chuàng)建靶向多種腫瘤類型的CAR。B7-H6在各種原發(fā)性人類腫瘤上表達(dá),包括白血病、淋巴瘤和胃腸道間質(zhì)瘤,但在正常組織上不是組成型表達(dá)的。
B7-H6用戶評(píng)價(jià)
關(guān)鍵字: B7-H6;B7-H6蛋白;B7 Homolog 6;B7H6;B7H6蛋白;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。